Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

SK Biopharmaceuticals has filed a supplemental NDA with the FDA to expand cenobamate (Xcopri) beyond focal-onset seizures to primary generalized tonic-clonic (PGTC) seizures. A phase 3 trial of 169 patients showed a 71.9% median seizure reduction with cenobamate versus 39.6% with placebo. The company also filed separately to extend the drug's use to pediatric patients and for an oral suspension formulation.
SK Biopharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA seeking approval of cenobamate (Xcopri) for primary generalized tonic-clonic (PGTC) seizures — a meaningful expansion beyond its current approval for focal-onset seizures in adults. The move is part of a trio of regulatory filings announced together, signaling a broader push to reach more patients living with epilepsy.
The PGTC application is backed by a global phase 3 trial (YKP3089C025) that enrolled 169 patients aged 12 and older across 12 countries. Cenobamate delivered a 71.9% median reduction in PGTC seizure frequency versus 39.6% with placebo, with 43.4% of treated patients achieving complete seizure freedom during the maintenance period. Safety results were consistent with the drug's known profile — no new signals, no DRESS cases, and no treatment-related deaths.
By the Numbers:
Why it matters: If approved, cenobamate would join a rare group of antiseizure medications labeled for both focal and generalized seizure types — broadening treatment options for a condition that affects millions worldwide, including adolescents.